Literature DB >> 8555790

Selegiline in Parkinson's disease.

D B Calne.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8555790      PMCID: PMC2551489          DOI: 10.1136/bmj.311.7020.1583

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


× No keyword cloud information.
  10 in total

1.  The antiparkinson efficacy of deprenyl derives from transient improvement that is likely to be symptomatic.

Authors:  M Schulzer; E Mak; D B Calne
Journal:  Ann Neurol       Date:  1992-12       Impact factor: 10.422

2.  The effect of deprenyl (selegiline) on the natural history of Parkinson's disease.

Authors:  J W Tetrud; J W Langston
Journal:  Science       Date:  1989-08-04       Impact factor: 47.728

3.  Selegiline as an adjunct to conventional levodopa therapy in Parkinson's disease. Experience with this type B monoamine oxidase inhibitor in 200 patients.

Authors:  T S Elizan; M D Yahr; D A Moros; M R Mendoza; S Pang; C A Bodian
Journal:  Arch Neurol       Date:  1989-12

4.  Selegiline in de novo parkinsonian patients: the French selegiline multicenter trial (FSMT).

Authors:  H Allain; J Cougnard; H C Neukirch
Journal:  Acta Neurol Scand Suppl       Date:  1991

Review 5.  The oxidant stress hypothesis in Parkinson's disease: evidence supporting it.

Authors:  S Fahn; G Cohen
Journal:  Ann Neurol       Date:  1992-12       Impact factor: 10.422

Review 6.  The free radical hypothesis in idiopathic parkinsonism: evidence against it.

Authors:  D B Calne
Journal:  Ann Neurol       Date:  1992-12       Impact factor: 10.422

7.  Does selegiline delay progression of Parkinson's disease? A critical re-evaluation of the DATATOP study.

Authors:  C D Ward
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-02       Impact factor: 10.154

8.  Selegiline as initial treatment in de novo parkinsonian patients.

Authors:  V V Myllylä; K A Sotaniemi; J A Vuorinen; E H Heinonen
Journal:  Neurology       Date:  1992-02       Impact factor: 9.910

9.  Comparative study of selegiline plus L-dopa-carbidopa versus L-dopa-carbidopa alone in the treatment of Parkinson's disease.

Authors:  T Brannan; M D Yahr
Journal:  Ann Neurol       Date:  1995-01       Impact factor: 10.422

10.  Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: a longterm study.

Authors:  W Birkmayer; J Knoll; P Riederer; M B Youdim; V Hars; J Marton
Journal:  J Neural Transm       Date:  1985       Impact factor: 3.575

  10 in total
  3 in total

1.  Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Parkinson's disease is rarely a primary cause of death.

Authors:  M T Silva; P M Watts; P Jenner
Journal:  BMJ       Date:  1996-03-16

2.  Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Stopping selegeline may lead to problems for patients.

Authors:  K E Anderson; A C Girdwood; J A Wilson
Journal:  BMJ       Date:  1996-03-16

Review 3.  Monoamine oxidase B inhibitors for early Parkinson's disease.

Authors:  A D Macleod; C E Counsell; N Ives; R Stowe
Journal:  Cochrane Database Syst Rev       Date:  2005-07-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.